FIELD: medicine.
SUBSTANCE: invention proposes using percutaneous therapeutic system inducing high plasma levels of rotigotin for producing anti-parkinsonic medicinal agent and a method for treatment of Parkinson's disease. Proposed system involves rotigotin in the concentration from 0.1 to 3.15 mg/cm2 in form of free base and silicone representing a mixture of at least one pressure-sensitive stick silicone adhesive (Q7-4301) and at least one pressure-sensitive silicone adhesive with mean stickness (Q7-4201). This provides an average plasma concentration of rotigotin from 0.4 to 2.0 ng/ml for 24 h after its applying.
EFFECT: enhanced medicinal effectiveness of system.
10 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED TRANSCUTANEOUS THERAPY SYSTEM FOR TREATING PARKINSON DISEASE CASES | 2002 |
|
RU2273477C2 |
| FORMULATION FOR TRANSEPICUTAL ADMINISTRATION IN TREATMENT OF RESTLESS LEGS SYNDROME | 2003 |
|
RU2301063C2 |
| DEVICE FOR TRANSDERMAL INTRODUCTION OF ROTIGOTINE IN ORGANISM IN FORM OF BASE | 2003 |
|
RU2340339C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM | 2006 |
|
RU2450805C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL INJECTION OF GUANFACINE, CONTAINING SILICONE POLYMER | 2018 |
|
RU2792822C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL ADMINISTRATION OF GUANFACINE CONTAINING AT LEAST ONE EXCIPIENT | 2018 |
|
RU2812734C2 |
| IONTOPHORETIC ROTIGOTINE DELIVERY IN TREATMENT FOR PARKINSON'S DISEASE | 2003 |
|
RU2339372C2 |
| THERMOFUSIBLE TTS FOR APPLYING ROTIGOTIN | 2003 |
|
RU2304434C2 |
| DEXTROMETHORPHAN TRANSDERMAL DELIVERY DEVICE | 2018 |
|
RU2795729C2 |
| IONOPHORETIC DELIVERY OF ROTIGOTINE FOR TREATMENT OF PARKINSON DISEASE | 2008 |
|
RU2478383C2 |
